How Much Semaglutide Is in Ozempic, and What That Means for Weight Loss in the UK

What the semaglutide doses in Ozempic tell us, and what they don't

Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that slows gastric emptying, reduces appetite and influences blood-sugar regulation. Ozempic delivers it at 0.5mg, 1mg or 2mg weekly, calibrated through the SURPASS and SUSTAIN diabetes trial programme for glycaemic control in adults with type 2 diabetes. Those doses work well for that purpose. They were not the doses tested in the large weight-management trials, and the Ozempic licence from the MHRA does not extend to weight loss, a point the NHS medicines page on semaglutide states plainly.

Wegovy uses the same molecule but steps up to a 2.4mg maintenance dose, titrated over roughly five months. The STEP 1 trial (published in the New England Journal of Medicine) found an average body-weight reduction of around 15% over 68 weeks at that dose, alongside lifestyle changes. The 7.2mg single-dose Wegovy pen, approved by the MHRA in April 2026, pushed average reductions to around 20.7% in trials. The dose in Ozempic simply does not reach those levels, which is why prescribing it for weight loss would be off-label and why the MHRA and NHS have been clear that Ozempic is not a weight-loss medicine. If someone is offering you Ozempic for weight management, that is a prompt to ask harder questions.

For a fuller breakdown of how semaglutide pricing works across products and doses, the picture is more detailed than most summary comparisons suggest.

What private semaglutide for weight loss actually costs in the UK, the honest version

Because Ozempic cannot legally be prescribed for weight loss through a regulated UK service, the relevant cost question is really about Wegovy. Private treatment is priced per pen or per monthly supply, and the total cost varies by dose, provider and what the headline figure actually covers. Eli Lilly's decision to raise Mounjaro's UK list price significantly from September 2025 (widely reported at the time) created pressure across the GLP-1 market, but Wegovy pricing has its own trajectory, and if you want to understand the latest Ozempic and Wegovy price cuts in context, the picture has shifted more than most people realise. Typical private monthly costs for semaglutide injection for weight management have ranged roughly £149 to £375 depending on dose and provider, though those figures shift and should be treated as context, not quotes. A dedicated Wegovy price page gives more current framing.

What the headline number often leaves out: some providers charge separately for the clinical consultation that the law requires before any prescription can be issued, for the prescription itself, for follow-up aftercare, and for delivery. A figure that looks straightforward may become considerably less so by the time the medicine arrives. That matters especially if you are ordering around a bank holiday or booking ahead before a busy week, the all-in cost is the only one worth comparing.

At nume, one price covers the consultation, prescription, treatment, and free next-working-day delivery. We are not going to claim to be the cheapest option available. That is deliberate: the people reviewing your consultation are GPhC-registered Independent Prescribers, not automated systems, and the infrastructure around that costs money we think is worth spending. Current treatment pricing is shown on the consultation and treatment page.

Why 'cheapest' is the wrong question for a prescription-only medicine

Semaglutide (in both its Wegovy and Ozempic forms) is a Prescription-Only Medicine. The MHRA has warned publicly about counterfeit weight-loss pens sold via social media and unverified online sellers, including fake pens found to contain insulin rather than the claimed medicine, leading to hospitalisations. In 2025 alone, around 20 million doses of illegally traded weight-loss medicines worth approximately £45m were seized. The pattern is consistent: sellers who operate without a prescription requirement, offer prices far below the market rate, or promote discount codes for POMs are red flags, not bargains. You can verify any online pharmacy against the GPhC register at pharmacyregulation.org/registers before handing over payment or personal details.

The MHRA's guidance is explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and a legitimate service will not present them that way. For a prescription medicine, the question is not which listing is cheapest but whether the clinical assessment is genuine, the supply chain is licensed, and someone qualified is watching out for you throughout treatment. See how the cost comparison between Ozempic and Wegovy breaks down in more detail, or explore which is actually cheaper when you price them honestly.

What IS licensed and available for weight loss, and how to access it

Two injectable medicines are currently licensed by the MHRA for weight management in UK adults: Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). Mounjaro is a dual GIP and GLP-1 receptor agonist (the only one of its kind licensed for weight loss in the UK) and SURMOUNT-5, a head-to-head trial published in the New England Journal of Medicine in 2025, found it produced greater average weight reduction than semaglutide 2.4mg. As of summer 2026, the Wegovy tablet is also licensed: the first oral GLP-1 medicine approved in the UK for weight management, approved by the MHRA on 11 June 2026. Rybelsus (also oral semaglutide, but at 3mg, 7mg and 14mg) is licensed for type 2 diabetes, not weight management, and should not be confused with the Wegovy tablet.

None of these are Ozempic. If your interest is in semaglutide for weight loss, Wegovy is the licensed product to explore, and if you are weighing up the titration steps, you can find out more about what the Wegovy 2.7mg dose costs as part of working out whether the full course fits your budget, while the Ozempic semaglutide injection price page helps clarify how the two products compare on cost for those who want the full picture. The broader treatment options page sets out how the medicines compare for different people and situations. A clinical review with one of our prescribers is the place where that decision is actually made. Check your eligibility and start your free consultation.